What Eli Lilly's Mounjaro videos show — and what they leave out

Is the video showing you the right pen for your dose?

One of the most useful things Eli Lilly's Mounjaro instructional footage does is show the KwikPen mechanism clearly: the dose window, the click that confirms injection, and the needle-cover that locks after use. If you are newly prescribed and uncertain whether the pen has worked, the visual confirmation sequence matters. Each KwikPen is pre-set to your prescribed strength, so the video applies across the dose range (2.5 mg through 15 mg) because the pen design is consistent. What changes with each dose step is the clinical rationale, and that is explained by your prescriber, not Lilly's camera crew.

Treatment starts at 2.5 mg for the first four weeks. That starting dose is a tolerability measure: the body gets time to adjust to the medicine before the dose is titrated upward. Lilly's videos do not instruct patients on when to move up; they show the mechanics of the pen. Timing and titration are your prescriber's territory. If you want the background on how the dose steps work, Eli Lilly's Mounjaro information on their UK site covers the licensed dose schedule in plain language.

The Mounjaro overview on our treatment pages also walks through what the prescription journey looks like from a patient's perspective, which many people find useful alongside the manufacturer's video.

What the video does not show: storage between injections

Lilly's instructional footage focuses on the injection moment, but the time between injections is where most handling errors happen. Mounjaro must be refrigerated at 2–8°C between uses. In practice, many people keep the pen in the fridge door, convenient, consistent, easy to remember. The exact permitted room-temperature window (for travel or when a fridge is not available) is stated in the Patient Information Leaflet that comes with your pen; the NHS tirzepatide guidance also covers this, and we always direct patients to the leaflet rather than summarise it here, because the window is specific and following it precisely matters.

The video also does not cover site rotation in the granular way the SmPC does. Injecting the same spot repeatedly can cause localised reactions; the abdomen, thigh, and upper arm are the licensed sites, and the general rule is to move around within each area rather than returning to the exact same point week after week.

For more detail on technique alongside the official footage, our Mounjaro injection video guide brings together the key handling points in one place.

Side effects you should know about before you press play

Lilly's patient-facing videos are careful not to minimise side effects, but they are also not the best place to get a full picture of what to watch for. The most common effects reported in clinical trials and on the NHS tirzepatide patient page are gastrointestinal: nausea, loose stools, constipation, indigestion, and burping tend to cluster around dose increases and usually ease within a couple of weeks. Fatigue and injection-site reactions are also reported.

More serious signs to take seriously: severe stomach pain that spreads toward the back, with or without vomiting, should prompt urgent medical attention, this can indicate pancreatitis, which the MHRA identified as a known but infrequent risk in its January 2026 Drug Safety Update for GLP-1 medicines. Gallbladder symptoms, signs of dehydration after prolonged vomiting or diarrhoea, and any allergic reaction also warrant prompt contact with a healthcare professional. Suspected side effects can be reported through the Yellow Card scheme.

If you are comparing how tirzepatide and semaglutide differ in their side-effect profiles, the tirzepatide detail page covers the mechanism and the clinical evidence together.

The decision the video cannot make for you

Instructional video is genuinely useful once you are prescribed. It is not a substitute for clinical assessment. Mounjaro is licensed in the UK for adults with a BMI of 30 or above, or 27 or above alongside a qualifying weight-related condition such as high blood pressure, high cholesterol, or type 2 diabetes. Lower thresholds apply for some ethnic backgrounds under UK guidance. BMI alone does not determine suitability, a prescriber reviews the whole clinical picture, including other medicines you take, your health history, and whether the starting dose is appropriate for you.

Cost is a factor for many people weighing up private treatment; you can find an honest breakdown of what affects Mounjaro pricing in the UK without inflated promises. And if you want to understand the broader weight-loss treatment landscape before committing to anything, our weight-loss treatment overview puts the options in context.

When you are ready to find out whether Mounjaro is suitable for you, a real clinician at our pharmacy reviews your consultation the same day, no automated decisions, no waiting lists. Speak to our prescribers to get started.